In what extent we reached the standards of antiplatelet therapy in secondary prevention of myocardial infarction
Abstract
Appropriate pharmacologic control of platelet aggregation represents pivotal treatment target in acute phase of myocardial infarction and in secondary prevention. It is evident for several years, that clopidogrel-based dual antiplatelet treatment does not have a suitable efficacy in several patients.
Because of more favorable pharmacodynamics properties, ticagrelor represents more appropriate solution, but its extensive use was opposed by an economical reason. Moreover, recent findings show that patients with impaired glomerular filtration benefit from ticagrelor based treatment in a larger extent than those with maintained normal renal functions.
We analyzed the prescription data of antiplatelets in the Czech Republic and approximate, how many patients after myocardial infarction showed impaired renal function.